OBJECTIVE: To report the latest conditional survival estimates for patients with cancer in Queensland, Australia. DESIGN, SETTING AND PARTICIPANTS: Descriptive study of state-wide population-based data from the Queensland Cancer Registry on patients aged 15-89 years who were diagnosed with invasive cancer between 1982 and 2007. MAIN OUTCOME MEASURE: Conditional 5-year relative survival for the 13 most common types of invasive cancer, and all cancers combined. RESULTS: The prognosis for patients with cancer generally improves with each additional year that they survive. A significant excess in mortality compared with the general population ceases to occur within 10 years after diagnosis for survivors of stomach, colorectal, cervical and thyroid cancer and melanoma, with these groups having a conditional 5-year relative survival of at least 95% after 10 years. For the remaining cancers we studied (pancreatic, lung, breast, prostate, kidney, and bladder cancer, non-Hodgkin lymphoma, and leukaemia), conditional 5-year relative survival estimates (at 10 years after diagnosis) ranged from 82% to 94%, suggesting that patients in these cohorts continue to have poorer survival compared with the age-matched general population. CONCLUSIONS: Estimates of conditional survival have the potential to provide useful information for cancer clinicians, patients and their carers as they are confronted by personal and surveillance-related decisions. This knowledge may be effective in building realistic hope and helping people manage uncertainty about the future. We suggest that measures of conditional survival be incorporated into routine statistical reporting in Australia.
OBJECTIVE: To report the latest conditional survival estimates for patients with cancer in Queensland, Australia. DESIGN, SETTING AND PARTICIPANTS: Descriptive study of state-wide population-based data from the Queensland Cancer Registry on patients aged 15-89 years who were diagnosed with invasive cancer between 1982 and 2007. MAIN OUTCOME MEASURE: Conditional 5-year relative survival for the 13 most common types of invasive cancer, and all cancers combined. RESULTS: The prognosis for patients with cancer generally improves with each additional year that they survive. A significant excess in mortality compared with the general population ceases to occur within 10 years after diagnosis for survivors of stomach, colorectal, cervical and thyroid cancer and melanoma, with these groups having a conditional 5-year relative survival of at least 95% after 10 years. For the remaining cancers we studied (pancreatic, lung, breast, prostate, kidney, and bladder cancer, non-Hodgkin lymphoma, and leukaemia), conditional 5-year relative survival estimates (at 10 years after diagnosis) ranged from 82% to 94%, suggesting that patients in these cohorts continue to have poorer survival compared with the age-matched general population. CONCLUSIONS: Estimates of conditional survival have the potential to provide useful information for cancer clinicians, patients and their carers as they are confronted by personal and surveillance-related decisions. This knowledge may be effective in building realistic hope and helping people manage uncertainty about the future. We suggest that measures of conditional survival be incorporated into routine statistical reporting in Australia.
Authors: Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen Journal: Haematologica Date: 2013-09-13 Impact factor: 9.941
Authors: Judy Y Ou; Holly Spraker-Perlman; Andrew C Dietz; Rochelle R Smits-Seemann; Sapna Kaul; Anne C Kirchhoff Journal: Cancer Epidemiol Date: 2017-10-07 Impact factor: 2.984
Authors: Suzanne K Chambers; Xingqiong Meng; Pip Youl; Joanne Aitken; Jeff Dunn; Peter Baade Journal: Qual Life Res Date: 2011-12-27 Impact factor: 4.147
Authors: Faisal F Alabbas; Ssakher M Al-Otaibi; Majed H Chamsi Pasha; Abdullah M Alghamdi; Hisham M Al-Hindi; Mahmoud S Al-Ahwal; Basem S El-Deek Journal: J Cancer Educ Date: 2016-06 Impact factor: 2.037
Authors: Peter D Baade; Patrick Royston; Philipa H Youl; Martin A Weinstock; Alan Geller; Joanne F Aitken Journal: BMC Cancer Date: 2015-01-31 Impact factor: 4.430
Authors: Jeff Dunn; Shu Kay Ng; William Breitbart; Joanne Aitken; Pip Youl; Peter D Baade; Suzanne K Chambers Journal: Health Qual Life Outcomes Date: 2013-03-14 Impact factor: 3.186
Authors: A M Vanderwalde; C-L Sun; L Laddaran; L Francisco; S Armenian; J Berano-Teh; F L Wong; L Popplewell; G Somlo; A S Stein; A Nademanee; A Krishnan; N Kogut; S J Forman; S Bhatia Journal: Leukemia Date: 2012-11-07 Impact factor: 11.528